Evidence map›Paper›PMID 42058507›Full record

ArticleCell insight2026

Viperin weakens IFN-I-induced immune activity by facilitating STAT1 degradation through E3 ligase UBE4A.

Ying Miao, Yukang Yuan, Liping Qian, Yong Yu, Qun Cui, Tingting Zhang, Renxia Zhang, Qian Zhao, Zhize Li, Anning Miao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ying MiaoTranslational Clinical Immunology Key Laboratory of Sichuan Province, Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan, China.
Yukang YuanTranslational Clinical Immunology Key Laboratory of Sichuan Province, Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan, China.
Liping QianInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, 215123, Jiangsu, China.
Yong YuDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qun CuiInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, 215123, Jiangsu, China.
Tingting ZhangTranslational Clinical Immunology Key Laboratory of Sichuan Province, Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan, China.
Renxia ZhangInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, 215123, Jiangsu, China.
Qian ZhaoInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, 215123, Jiangsu, China.
Zhize LiTranslational Clinical Immunology Key Laboratory of Sichuan Province, Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan, China.
Anning MiaoDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, School of Medicine, Soochow University, Suzhou, 215123, Jiangsu, China.
Yanou LiDepartment of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, Collaborative Innovation Center of Hematology, School of Medicine, Soochow University, Suzhou, 215123, Jiangsu, China.
Jun WangDepartment of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, Collaborative Innovation Center of Hematology, School of Medicine, Soochow University, Suzhou, 215123, Jiangsu, China.
Sidong XiongInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, 215123, Jiangsu, China.
Hui ZhengTranslational Clinical Immunology Key Laboratory of Sichuan Province, Department of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viperin is considered as an antiviral protein known to directly target a variety of viruses. However, whether and how Viperin affects virus infection by targeting intracellular immune signaling remain unexplored. Here, we reveal that Viperin inhibits type-I interferon (IFN-I) antiviral immune signaling by degrading STAT1. We found that IFN-I upregulates the ubiquitin E3 ligase ITCH to degrade UBR5, while Viperin subsequently recruits another ubiquitin E3 ligase UBE4A to promote STAT1 ubiquitination and degradation to attenuate IFN-I signaling. Moreover, the multifunctional interfering peptide VS-IP1 can block Viperin-mediated STAT1 degradation, thus enhancing IFN-I antiviral immune function. This study reveals that Viperin is a suppressor of IFN-I immune signaling, which could renew understanding of the biological function of Viperin, and provide a strategy for enhancing clinical IFN-I therapeutic efficacy.

Indexed as

Antiviral immunityIFN-ISTAT1UBE4AUbiquitinationViperin

Identifiers

PMID42058507
PMCPMC13122806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.